Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.50 |
| ▸ | TNK2 | Q07912 | 11/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | ROS1 | P08922 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4774308 | 0.88 | CCNA2 (0.54) | CCNA2CDK2CCNA1TNK2CHEK1 | |
| SCHEMBL4766348 | 0.87 | CCNA2 (0.59) | CCNA2CDK2CCNA1TNK2CHEK1 | |
| SCHEMBL4770109 | 0.86 | CCNA2 (0.55) | CCNA2CDK2CCNA1TNK2POLB | |
| SCHEMBL4770586 | 0.84 | CCNA2 (0.59) | CCNA2CDK2CCNA1TNK2CHEK1 | |
| SCHEMBL4775363 | 0.82 | CCNA2 (0.54) | CCNA2CDK2CCNA1TNK2POLB | |
| SCHEMBL4766555 | 0.82 | CCNA2 (0.53) | CCNA2CDK2CCNA1TNK2POLB | |
| SCHEMBL4765289 | 0.82 | CCNA2 (0.57) | CCNA2CDK2CCNA1TNK2POLB | |
| SCHEMBL4772160 | 0.81 | CCNA2 (0.53) | CCNA2CDK2CCNA1TNK2CHEK1 | |
| SCHEMBL6220525 | 0.81 | CCNA2 (0.60) | CCNA2CDK2CCNA1POLBALDH1A1 | |
| SCHEMBL4768919 | 0.80 | CCNA2 (0.52) | CCNA2CDK2CCNA1TNK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303496-B9 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1303496-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| US-6908920-B2 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2005-06-21 | — | — | US | disclosed |
| US-20030216406-A1 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216406-A1 | Pyrimidine derivatives | TYMP, TYMS, CCNT1 | CCNA2 40/4885CDK2 24/4885CCNA1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.